Data on gastroenteropancreatic neuroendocrine neoplasms (NEN) G3 (well-differentiated neuroendocrine tumors (NET G3) and neuroendocrine carcinoma (NEC)) are limited. We retrospectively study patients with NET G3 and NEC from eight European centers. Data examined included clinical and pathological characteristics at diagnosis, therapies and outcomes. Two hundred and four patients were analyzed (37 NET G3 and 167 NEC). Median age was 64 (21-89) years. Tumor origin included pancreas (32%) and colon-rectum (27%). The primary tumor was resected in 82 (40%) patients. Metastatic disease was evident at diagnosis in 88% (liver metastases: 67%). Median Ki-67 index was 70% (30% in NET G3 and 80% in NEC; P!0.001). Median overall survival (OS) for all patients was 23 (95% CI: 18-28) months and significantly higher in NET G3 (99 vs 17 months in NEC; HRZ8.3; P!0.001). Platinum-etoposide first line chemotherapy was administered in 113 (68%) NEC and 12 (32%) NET G3 patients. Disease control rate and progression free survival (PFS) were significantly higher in NEC compared to NET G3 (P!0.05), whereas OS was significantly longer in NET G3 (PZ0.003). Second-and third-line therapies (mainly FOLFIRI and FOLFOX) were given in 79 and 39 of NEC patients; median PFS and OS were 3.0 and 7.6 months respectively after second-line and 2.5 and 6.2 months after third-line chemotherapy. In conclusion, NET G3 and NEC are characterized by significant differences in Ki-67 index and outcomes. While platinum-based chemotherapy is effective in NEC, it seems to have limited value in NET G3.
Introduction
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are rare tumors defined by the presence of specific biomarkers (Yao et al. 2008) . The differentiation status is a major prognostic factor, regardless of primary site and stage (Lepage et al. 2004 , Rindi et al. 2006 , Yao et al. 2008 . Moreover, the European Neuroendocrine Tumor Society (ENETS) developed a grading system (G1-G3) (Rindi et al. 2006) , which has a strong prognostic value for survival (Ferrone et al. 2007 , Pape et al. 2008 , Jann et al. 2011 , Panzuto et al. 2011 , Khan et al. 2013 . Grade 3 neoplasms (defined as having a high proliferative index with a Ki-67 O20%) are highly heterogeneous, containing tumors that are both well and poorly differentiated. The assumption that all NEN G3 should be considered as a single entity regarding diagnosis, prognosis and treatment has been challenged. Sorbye et al. (2013) proposed separating NEN G3 into two categories: those with a Ki-67 index ranging from 20 to 55% and those with a Ki-67 index above 55%. According to the current World Health Organization (WHO) 2010 Classification, neuroendocrine carcinoma (NEC) is defined by both a poorly differentiated morphology (large-cell or small-cell type) and a proliferative activity defined by mitotic count O20/10 HPF and/or Ki-67 index O20% (Bosman et al. 2010) . However, another subgroup of NEN that are not included in the recent WHO classification show a well-differentiated morphology, although associated with a G3 grade (neuroendocrine tumor (NET) G3) (Velayoudom-Cephise et al. 2013 , Basturk et al. 2014 . Based on their data, Velayoudom-Cephise et al. proposed a new classification for NEN G3 based on the combination of morphology and grade.
Data on NEN G3 are limited and retrospective:
i) GEP-NEC accounts for w10-20% of all GEP-NEN (Lepage et al. 2004 , Yao et al. 2008 ; they have a poor prognosis with a median survival of only 4-6 months in stage IV disease without treatment and up to 6-19 months in patients receiving the standard first-line, platinum-etoposide chemotherapy. In the course of the disease, almost all NEC show resistance to first-line chemotherapy. However, second-line treatment is not codified (Moertel et al. 1991 , Mitry et al. 1999 , Fjallskog et al. 2001 , Janson et al. 2010 , Strosberg et al. 2010 , Oberg et al. 2012 . The types and benefits of second-line therapeutic regimens still have to be evaluated. ii) Data on GEP-NET G3 are even more limited; they account for w10% of G3-GEP-NEN (Scoazec et al. 2012) . NET G3 appear to have a significantly more protracted clinical course than NEC. First-line therapy is not codified. It might be expected that they benefit from less aggressive chemotherapeutic regimens routinely used in NET G2 (e.g., temozolomide-based therapy).
The aim of this study was to describe characteristics, prognosis and response to treatment of GEP-NEN G3, comparing NET G3 (defined, as above: well-differentiated NET with a G3 grading) and NEC (Table 1) . For this purpose, we performed a retrospective analysis of a cohort of 204 patients with GEP-NEN G3, from eight European centers.
Patients and methods
Patients were identified from hospital chart codings and hospital databases. The inclusion criteria were: i) initial diagnosis of NEN G3 from January 2000 to December 2013, ii) histopathologically confirmed diagnosis by synaptophysin (Syn) and/or chromogranin A (CgA) positivity, iii) GEP primary or of unknown primary and iv) Ki-67 index O20% or poorly differentiated morphology. Mixed tumors (MANEC) and NEN G3 without morphological differentiation available were excluded. Regarding quality of the pathology data, all the centers involved are tertiary hospitals that have expert pathologists in NET reviewing the samples before multidisciplinary meetings.
Data captured included demographics (name of NET center, age at diagnosis, gender, date of diagnosis); clinical 
Results

Patient characteristics
Overall, 233 patients were included from eight tertiary centers. Twenty-nine (12%) patients were excluded due to violation of inclusion/exclusion criteria. Characteristics of the remaining 204 patients included in this multi-centric retrospective study are summarized in Table 2 . The majority of the patients (nZ136, 67%) were initially diagnosed from the beginning of 2010 onwards. The median time of follow-up of those patients alive was 14.5 (range 1.1-124.7) months. Patients were significantly younger in the NET G3 cohort (PZ0.001) and were significantly more likely to have a functional tumor compared to NEC (PZ0.003) ( Table 2 ). Primary localization was more often in the pancreas (65%) for NET G3, while colorectal NEC was more common than colorectal NET G3 (Table 2) . Nuclear medicine imaging did not identify a significant difference in FDG-PET uptake between both cohorts, but SRS uptake was more frequent and higher in NET G3 tumors.
Histopathology
Thirty-seven (18%) and 167 (79%) cases showed well differentiated or poorly differentiated morphological features respectively, defining them as NET G3 and NEC. The median Ki-67 value across all tumors was 70% (range 21-100), with the distribution of Ki-67 values in relation to differentiation displayed in Fig. 1 . Median Ki-67 in the NEC group (80%, range: 25-100) was significantly higher than in NET G3 (30%, range: 21-70; P!0.001). In those cases with Ki-67 O55%, almost all tumors were poorly differentiated, whereas the subgroup with a Ki-67 index of between 21 and 55% were very heterogeneous in terms of differentiation (Fig. 1) . A subgroup of NEC patients had the morphological description assessed according to the WHO 2010 definition; 55 (43%) had small-cell and 73 (57%) had large-cell carcinoma. The Ki-67 index was significantly higher in small-cell NEC vs large-cell NEC (80% vs 70%; PZ0.025). CgA and Syn staining were not significantly different between NET G3 and NEC, although NEC seemed to show less CgA staining (75% vs 91%, PZ0.08).
Survival
Over the study period, death was recorded in 110 of the patients (54%). Median OS across all of the patients was 22.8 (95% CI: 17.8-27.9) months (Fig. 2a) and was significantly higher (HRZ8.3 (95% CI: 2.9-23.81); P!0.001) in NET G3 (median 98.7 months, 95% CI: 53.9-143.5) than in NEC (median 17 months, 95% CI 13.5-20.5) (Fig. 2b) after multivariate analysis. Results of univariate analysis and cox regression on other prognostic factors for survival are summarized in Table 3 . TNM staging proved to be of prognostic relevance (Fig. 2c) , with statistical significance according to both univariate and multivariate analysis. Ki-67 O55% was associated with worse survival at univariate analysis, but not at multivariate analysis.
Treatment
Twelve (32%) patients with NET G3 and 113 (68%) patients with NEC were treated by a platinum-etoposide first-line chemotherapy, 1.0 (0-71.5) months after the diagnosis. In this platinum-treated population, disease control rate (DCR) (33% vs 68%; PZ0.03) and median PFS (2.4 vs 5.0 months; PZ0.049) were significantly lower in NET G3 compared to NEC respectively, while median OS remained significantly longer in NET G3 than in NEC patients (PZ0.003) ( Table 5 ; median PFS was w3 months and 2.5 months respectively.
Discussion
With regard to the current WHO classification (2010), NEC is considered both, a tumor that is defined by its high proliferative activity and also by its poorly differentiated tumor morphology. Morphology has played an important role in defining tumors in the past, but now this parameter may be being neglected within routine care, as the definition of NEC is often given by just providing its grade. This is reflected by the most recent publications of NEN G3, where tumor morphology is not even mentioned (Welin et al. 2011 , Sorbye et al. 2013 . While most NEN G3 are of poorly differentiated morphology, there is a subgroup of well-differentiated NET with G3 grading that is not reflected by the latest WHO classification. Furthermore, although Ki-67 is key to the grading system adopted by WHO, we show that morphology was found to be more informative than the Ki-67 index to stratify NEN G3 patients outcomes. Usually, NET G3 have a consistently lower Ki-67 index compared to NEC, ranging between 20 and 50%.
Several studies have challenged the assumption that NET G3 and NEC are overlapping entities. It has been suggested that these two cancers differ in terms of prognosis, SRS uptake and response to chemotherapy regimens (Vilar et al. 2007 , Velayoudom-Cephise et al. 2013 . The response to first-line platinum-etoposide represents one of the most relevant disparities. Velayoudom-Cephise et al. (2013) reported 0% objective response in NET G3 patients vs 31% in large-cell NEC patients. This was in agreement with the results of the NORDIC study, which compared subgroups with Ki-67 !55% vs O55%, recording objective response rates of 15% vs 42% respectively (Sorbye et al. 2013 ). In our study, the response rates to platinum-etoposide were similar to those reported in the above-mentioned studies (39% vs 2% for NEC and NET G3 respectively), underlining the fact that differentiation is key when considering the sensitivity to the standard first-line chemotherapy. We hypothesize that NET G3 could have been enrolled in Sorbye's study, explaining the lower response rate to platinum-etoposide within the group of tumors with a Ki-67 !55, particularly from pancreas localization. Among our NEC patients, we reported similar responses between duodeno-pancreatic and colorectal primaries. A trend exists of better response to platinum-etoposide in smallcell vs large-cell NEC. Limited data and no guidelines are currently available for managing patients with NET G3. The observation that most experts feel these cases to be different from NEC is supported by their first choice to use (Welin et al. 2011 , Hentic et al. 2012 , Olsen et al. 2012 , Olsen et al. 2014 , Hadoux et al. 2015 . Published trials have included very heterogeneous populations, which make direct comparisons impossible. In particular, a retrospective study of temozolomide G capecitabine G bevacizumab in 25 patients included mainly patients with a Ki-67 between 20 and 30%; it reported an objective response rate of 32% (Welin et al. 2011) . However, it is difficult to recommend temozolomide as an optional treatment for all NEN G3 based on this analysis, or for all NET G3 irrespective of their primary tumor site. Furthermore, the morphological feature was not a variable considered in this particular report. On the contrary, a study reported the efficacy of FOLFIRI as second-line therapy in a NEC population with a median Ki-67 of 50%, excluding NET G3 (Hentic et al. 2012) . Similar results were obtained by Hadoux et al. (2015) using FOLFOX in a similar population. A retrospective study, using topotecan in 22 patients with clearly poorly differentiated tumors with a median Ki-67 of 95%, showed no convincing anti-tumor activity (Olsen et al. 2014) .
Our study presents one of the largest well-characterized cohorts of NEN G3. We analyzed these data with the aim of generating hypotheses to drive further clinical trials. In this respect, retrospective series are key to generating new approaches in this rare disease in which it is difficult to conduct randomized trials. Retrospective collection of data has common well-known biases, such as the detection bias (the data collected are those from the longest survivors). Another potential weakness of this study was the lack of blinded centralized pathology review to ensure perfect accuracy regarding classification of morphology; however, all centers were expert NET groups with recognized and experienced pathologists in this field. In addition, all the centers recruiting patients were tertiary hospitals, which might have affected the patient survival and the chemotherapy schedules applied.
In conclusion, in our study, differentiation was the strongest independent factor for OS. Grade 3 NEN represent a heterogeneous disease that makes clinical decisions extremely difficult. Strikingly, platinum-based chemotherapy was not the first choice of treatment for NET G3 and seemed significantly less effective in NET G3 compared to NEC. This latter fact shows that within the NET expert community NET G3 and NEC are considered clearly a different entity. Finally, our study presents interesting data on the efficacy of second-and third-line treatment of NEC, which could be useful in designing new prospective studies.
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